主要风险是， 如果FDA禁止复合GLP-1复合药物的新闻导致股价下跌，即使Hims & Hers Health准确地表示其个性化服务对业务的影响有限，市场也可能轻易忽视其强劲的核心业务， 直到在线健康平台证明GLP-1复合药物业务并非 驱动力 ...

Hims & Hers Health ( HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth ...

Discover why Hims & Hers Health is a top telehealth leader with impressive growth potential and a promising future for ...

美银证券的分析师强调了诺和诺德公司最近的行动可能会影响Hims & Hers的战略。上周，诺和诺德公司向FDA提交了一份公民请愿书，寻求限制复合药房生产其糖尿病药物Victoza（通用名为liraglutide）的仿制版。

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on Substack by Antonio Linares. In this article, we will ...

Financial writer highlights undervalued Hims & Hers Health with impressive growth potential and innovative product launches, ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...